Details

Autor(en) / Beteiligte

• Zhao, Ming
• Guo, Zhi
• Zou, Ying-Hua
• Li, Xiao
• Yan, Zhi-Ping
• Chen, Min-Shan
• Fan, Wei-Jun
• Li, Hai-Liang
• Yang, Ji-Jin
• Chen, Xiao-Ming
• Xu, Lin-Feng
• Zhang, Yue-Wei
• Zhu, Kang-Shun
• Sun, Jun-Hui
• Li, Jia-Ping
• Jin, Yong
• Yu, Hai-Peng
• Duan, Feng
• Xiong, Bin
• Yin, Guo-Wen
• Lin, Hai-Lan
• Ma, Yi-Long
• Wang, Hua-Ming
• Gu, Shan-Zhi
• Si, Tong-Guo
• Wang, Xiao-Dong
• Zhao, Chang
• Yu, Wen-Chang
• Guo, Jian-Hai
• Zhai, Jian
• Huang, Yong-Hui
• Wang, Wei-Yu
• Lin, Hai-Feng
• Gu, Yang-Kui
• Chen, Jin-Zhang
• Wang, Jian-Peng
• Zhang, Yi-Min
• Yi, Jun-Zhe
• Lyu, Ning

Titel

Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations

Ist Teil von

• Hepatology international, 2024-02, Vol.18 (1), p.4-31

Ort / Verlag

New Delhi: Springer India

Erscheinungsjahr

2024

Quelle

springer (창간호~2014)

Beschreibungen/Notizen

• Hepatocellular carcinoma (HCC) is one of the most common malignancies and the third leading cause of cancer-related deaths globally. Hepatic arterial infusion chemotherapy (HAIC) treatment is widely accepted as one of the alternative therapeutic modalities for HCC owing to its local control effect and low systemic toxicity. Nevertheless, although accumulating high-quality evidence has displayed the superior survival advantages of HAIC of oxaliplatin, fluorouracil, and leucovorin (HAIC-FOLFOX) compared with standard first-line treatment in different scenarios, the lack of standardization for HAIC procedure and remained controversy limited the proper and safe performance of HAIC treatment in HCC. Therefore, an expert consensus conference was held on March 2023 in Guangzhou, China to review current practices regarding HAIC treatment in patients with HCC and develop widely accepted statements and recommendations. In this article, the latest evidence of HAIC was systematically summarized and the final 22 expert recommendations were proposed, which incorporate the assessment of candidates for HAIC treatment, procedural technique details, therapeutic outcomes, the HAIC-related complications and corresponding treatments, and therapeutic scheme management.